Abstract:<h3 class="Heading">Purpose</h3><p class="Para">Defining robust criteria for drug activity in preclinical studies allows for fewer animals per treatment group, and potentially allows for inclusion of additional cancer models that more accurately represent genetic diversity and, potentially, allows for tumor sensitivity biomarker identification.</p><h3 class="Heading">Methods</h3><p class="Para">Using a single-mouse design, 32 pediatric xenograft tumor models representing diverse pediatric cancer types [Ewing sarcoma (9), brain (4), rhabdomyosarcoma (10), Wilms tumor (4), and non-CNS rhabdoid tumors (5)] were evaluated for response to a single administration of pegylated-SN38 (PLX038A), a controlled-release PEGylated formulation of SN-38. Endpoints measured were percent tumor regression, and event-free survival (EFS). The correlation between response to PLX038A was compared to that for ten models treated with irinotecan (2.5 mg/kg × 5 days × 2 cycles), using a traditional design (10 mice/group). Correlations between tumor sensitivity, genetic mutations and gene expression were sought. Models showing no disease at week 20 were categorized as 'extreme responders' to PLX038A, whereas those with EFS less than 5 weeks were categorized as 'resistant'.</p><h3 class="Heading">Results</h3><p class="Para">The activity of PLX038A was evaluable in 31/32 models. PLX038A induced > 50% volume regressions in 25 models (78%). Initial tumor volume regression correlated only modestly with EFS (<em class="EmphasisTypeItalic">r</em><sup>2</sup> = 0.238), but sensitivity to PLX038A was better correlated with response to irinotecan when one tumor hypersensitive to PLX038A was omitted (<em class="EmphasisTypeItalic">r</em><sup>2</sup> = 0.6844). Mutations in <em class="EmphasisTypeItalic">53BP1</em> were observed in three of six sensitive tumor models compared to none in resistant models (<em class="EmphasisTypeItalic">n</em> = 6).</p><h3 class="Heading">Conclusions</h3><p class="Para">This study demonstrates the feasibility of using a single-mouse design for assessing the antitumor activity of an agent, while encompassing greater genetic diversity representative of childhood cancers. PLX038A was highly active in most xenograft models, and tumor sensitivity to PLX038A was correlated with sensitivity to irinotecan, validating the single-mouse design in identifying agents with the same mechanism of action. Biomarkers that correlated with model sensitivity included wild-type <em class="EmphasisTypeItalic">TP53</em>, or mutant <em class="EmphasisTypeItalic">TP53</em> but with a mutation in <em class="EmphasisTypeItalic">53BP1</em>, thus a defect in DNA damage response. These results support the value of the single-mouse experimental design.</p>

Supplemental Table 2 from Evaluation of Alternative <i>in Vivo</i> Drug Screening Methodology: A Single Mouse Analysis

Supplemental Figure 1 from Evaluation of Alternative <i>in Vivo</i> Drug Screening Methodology: A Single Mouse Analysis

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Table S1 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Supplementary Table S4 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Supplementary Table S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Supplementary Table S3 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Prospective use of the single-mouse experimental design for the evaluation of PLX038A

Data Supplement from Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?

The design, analysis and application of mouse clinical trials in oncology drug development

Supplementary Table S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Multiple reaction monitoring assays for large-scale quantitation of proteins from 20 mouse organs and tissues

Supplementary Data S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model

Evaluation of Variability across Rat Acute Oral Systemic Toxicity Studies

The selection of animal models influences the assessment of anti-tumor efficacy: promising sialic acid-conjugate modified liposomes demonstrate remarkable therapeutic effects in diverse mouse strains

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Abstract 6892: Murine ex vivo platform: A powerful tool for biomarker assessment and high throughput screening of translationally relevant in vivo tumor models for PD and efficacy studies

Invariant Risk Minimisation for Cross-Organism Inference: Substituting Mouse Data for Human Data in Human Risk Factor Discovery

Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplemental Table 2 from Evaluation of Alternative &lt;i&gt;in Vivo&lt;/i&gt; Drug Screening Methodology: A Single Mouse Analysis

Supplemental Figure 1 from Evaluation of Alternative &lt;i&gt;in Vivo&lt;/i&gt; Drug Screening Methodology: A Single Mouse Analysis